Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 6, pp 837–838 | Cite as

In-hospital mortality for toxic megacolon

  • Rachele CiccocioppoEmail author
  • Gino Roberto Corazza
IM - COMMENTARY

Toxic megacolon (TM) is a life-threatening condition that develops when severe colonic inflammation originating from any kind of mucosal injury (immune-mediated, infective, ischaemic, neoplastic, iatrogenic) causes muscular atony and systemic toxicity [1]. Despite its reduced prevalence, the outcome is still unsatisfactory, and a substantial number of patients undergo colectomy. In this context, the paper by Doshi and coworkers [2], reporting the results of the analysis of the data collected in the Nationwide Inpatient Sample database from January 2010 through December 2014, is of interest and offers some food for thought. Obviously, it has some intrinsic weaknesses related to the retrospective design of the study, the absence of a control group, and the overestimation of the prevalence of TM due to the lack of differentiation between first admission and subsequent re-admission of the same patient. Nonetheless, the identification of those factors associated with a poor outcome...

Abbreviations

CD

Clostridium difficile

IBD

Inflammatory bowel diseases

TM

Toxic megacolon

Notes

Compliance with ethical standards

Conflict of interest

The authors have no potential conflicts of interest to declare.

Statement of human and animal rights

The work was carried out in agreement with the Declaration of Helsinki.

Informed consent

No informed consent was necessary for the study.

References

  1. 1.
    Autenrieth D, Baumgart DC (2012) Toxic megacolon. Inflamm Bowel Dis 18:584–591.  https://doi.org/10.1002/ibd.21847 CrossRefPubMedGoogle Scholar
  2. 2.
    Doshi R, Desai J, Shah Y, Decter D, Doshi S (2018) Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States. Intern Emerg Med.  https://doi.org/10.1007/s11739-018-1889-8 PubMedCrossRefGoogle Scholar
  3. 3.
    Lee DY, Chung EL, Guend H, Whelan RL, Wedderburn RV, Rose KM (2014) Predictors of mortality after emergency colectomy for Clostridium difficile colitis. An analysis of ACS-NSQIP. Ann Surg 259:148–156.  https://doi.org/10.1097/sla.0b013e31828a8eba CrossRefPubMedGoogle Scholar
  4. 4.
    Caprilli R, Vernia P, Colaneri O, Torsoli A (1976) Blood pH: a test for assessment of severity in proctocolitis. Gut 17:763–769CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hokama A, Ohira T, Kishimoto K, Kinjo F, Fujita J (2012) Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis. Intern Emerg Med 7:487–488.  https://doi.org/10.1007/s11739-012-0834-5 CrossRefPubMedGoogle Scholar
  6. 6.
    Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449.  https://doi.org/10.1056/nejmoa051639 CrossRefPubMedGoogle Scholar
  7. 7.
    Eze P, Balsells E, Kyaw MH, Nair H (2017) Risk factors for Clostridium difficile infections—an overview of the evidence base and challenges in data synthesis. J Global Health 7:010417.  https://doi.org/10.7189/jogh.07.010417 CrossRefGoogle Scholar
  8. 8.
    Curry SR (2017) Clostridium difficile. Clin Lab Med 37:341–369.  https://doi.org/10.1016/j.cll.2017.01.007 CrossRefPubMedGoogle Scholar
  9. 9.
    Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT (2017) Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 152:1889–1900.  https://doi.org/10.1053/j.gastro.2017.02.003 CrossRefPubMedGoogle Scholar
  10. 10.
    Cammarota G, Ianiro G, Tilg H et al (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66:569–580.  https://doi.org/10.1136/gutjnl-2016-313017 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Villafuerte Gálveza JA, Kellya CP (2017) Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection. Exp Rev Gastroenterol Hepatol 11:611–622.  https://doi.org/10.1080/17474124.2017.1344551 CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  1. 1.Gastroenterology Unit, Department of Medicine, AOUI Policlinico G.B. RossiUniversity of VeronaVeronaItaly
  2. 2.Clinica Medica I, Department of Internal Medicine, IRCCS San Matteo Hospital FoundationUniversity of PaviaPaviaItaly

Personalised recommendations